Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes with recalcitrant DME, who have received a mi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993621002061 |
| _version_ | 1819199373021544448 |
|---|---|
| author | Debdulal Chakraborty Jay U. Sheth Subhendu Boral Tushar K. Sinha |
| author_facet | Debdulal Chakraborty Jay U. Sheth Subhendu Boral Tushar K. Sinha |
| author_sort | Debdulal Chakraborty |
| collection | DOAJ |
| description | Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes with recalcitrant DME, who have received a minimum of ten intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, underwent IVI brolucizumab and were followed-up for minimum of 16 weeks. Patients underwent best-corrected visual acuity (BCVA) testing, ophthalmic examination, and optical coherence tomography at baseline and all the scheduled follow-up visits (Weeks 4, 8, 12, and 16). All three patients demonstrated notable improvement in BCVA and reduction in the fluid on SD-OCT lasting up to week 12. At week 16, all three eyes maintained the visual acuity gains. However, early increase in fluid was noted in all the three cases, for which second dose of IVI brolucizumab was planned. No ocular or systemic adverse events were noted in any of the cases. Conclusions and Importance: In this real-world case series, treatment with IVI brolucizumab exhibited excellent visual acuity outcomes lasting up to 16 weeks for the treatment of recalcitrant DME. Single dose IVI brolucizumab achieves good anatomical improvement based on SD-OCT persisting up to 12 weeks, followed by early recurrence of fluid at week 16. The results did not show any ocular or systemic safety concerns for IVI brolucizumab. |
| first_indexed | 2024-12-23T03:15:18Z |
| format | Article |
| id | doaj.art-64de30e385444aeda8da85962d8516c0 |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-23T03:15:18Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-64de30e385444aeda8da85962d8516c02022-12-21T18:02:07ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362021-12-0124101197Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case seriesDebdulal Chakraborty0Jay U. Sheth1Subhendu Boral2Tushar K. Sinha3Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, India; Corresponding author.Department of Vitreoretinal Services, Surya Eye Institute and Research Center, Mumbai, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, IndiaDepartment of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, IndiaPurpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes with recalcitrant DME, who have received a minimum of ten intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, underwent IVI brolucizumab and were followed-up for minimum of 16 weeks. Patients underwent best-corrected visual acuity (BCVA) testing, ophthalmic examination, and optical coherence tomography at baseline and all the scheduled follow-up visits (Weeks 4, 8, 12, and 16). All three patients demonstrated notable improvement in BCVA and reduction in the fluid on SD-OCT lasting up to week 12. At week 16, all three eyes maintained the visual acuity gains. However, early increase in fluid was noted in all the three cases, for which second dose of IVI brolucizumab was planned. No ocular or systemic adverse events were noted in any of the cases. Conclusions and Importance: In this real-world case series, treatment with IVI brolucizumab exhibited excellent visual acuity outcomes lasting up to 16 weeks for the treatment of recalcitrant DME. Single dose IVI brolucizumab achieves good anatomical improvement based on SD-OCT persisting up to 12 weeks, followed by early recurrence of fluid at week 16. The results did not show any ocular or systemic safety concerns for IVI brolucizumab.http://www.sciencedirect.com/science/article/pii/S2451993621002061BrolucizumabDiabetic macular edemaAnti-vascular endothelial growth factor |
| spellingShingle | Debdulal Chakraborty Jay U. Sheth Subhendu Boral Tushar K. Sinha Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series American Journal of Ophthalmology Case Reports Brolucizumab Diabetic macular edema Anti-vascular endothelial growth factor |
| title | Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series |
| title_full | Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series |
| title_fullStr | Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series |
| title_full_unstemmed | Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series |
| title_short | Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series |
| title_sort | off label intravitreal brolucizumab for recalcitrant diabetic macular edema a real world case series |
| topic | Brolucizumab Diabetic macular edema Anti-vascular endothelial growth factor |
| url | http://www.sciencedirect.com/science/article/pii/S2451993621002061 |
| work_keys_str_mv | AT debdulalchakraborty offlabelintravitrealbrolucizumabforrecalcitrantdiabeticmacularedemaarealworldcaseseries AT jayusheth offlabelintravitrealbrolucizumabforrecalcitrantdiabeticmacularedemaarealworldcaseseries AT subhenduboral offlabelintravitrealbrolucizumabforrecalcitrantdiabeticmacularedemaarealworldcaseseries AT tusharksinha offlabelintravitrealbrolucizumabforrecalcitrantdiabeticmacularedemaarealworldcaseseries |